OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
-15.12%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$375M
AUM Growth
+$375M
(-19%)
Cap. Flow
+$2.21M
Cap. Flow
% of AUM
0.59%
Top 10 Holdings %
Top 10 Hldgs %
91.67%
Holding
25
New
1
Increased
6
Reduced
8
Closed
5
Top Buys
Top Sells
| 1 |
iTeos Therapeutics
ITOS
|
$14.5M |
| 2 |
BridgeBio Pharma
BBIO
|
$12.1M |
| 3 |
IMAB
I-MAB
IMAB
|
$9.6M |
| 4 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
$6.76M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$6.52M |
Sector Composition
| 1 | Healthcare | 95.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $117M | 31.17% | 2,583,059 +243,000 | +10% | +$11M |
|
2
Arcus Biosciences
RCUS
$1.13B
| $67.7M | 18.06% | 2,669,974 +180,000 | +7% | +$4.56M |
|
|
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $44.6M | 11.91% | 2,551,703 +1,195,453 | +88% | +$20.9M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $26.3M | 7.02% | 330,000 +230,000 | +230% | +$18.3M |
|
5
Gossamer Bio
GOSS
$562M
| $23.1M | 6.16% | 2,758,069 +194,931 | +8% | +$1.63M |
|
6
Celldex Therapeutics
CLDX
$1.47B
| $20.5M | 5.48% | 761,398 | – | – |
|
7
SPDR S&P Biotech ETF
XBI
$5.07B
| $18.1M | 4.82% | 243,400 +187,600 | +336% | +$13.9M |
|
8
Stoke Therapeutics
STOK
$1.08B
| $10.1M | 2.69% | 763,456 -50,000 | -6% | -$660K |
|
|
9
BridgeBio Pharma
BBIO
$9.89B
| $8.48M | 2.26% | 933,743 -1,333,743 | -59% | -$12.1M |
|
10
Vera Therapeutics
VERA
$1.38B
| $7.83M | 2.09% | 575,000 | – | – |
|
11
Arvinas
ARVN
$568M
| $7.51M | 2.01% | 178,500 | – | – |
|
12
Avidity Biosciences
RNA
$5.99B
| $4.67M | 1.25% | 321,641 | – | – |
|
|
13
4D Molecular Therapeutics
FDMT
$288M
| $4.42M | 1.18% | 632,745 -934,150 | -60% | -$6.52M |
|
14
Keros Therapeutics
KROS
$618M
| $4.21M | 1.12% | 152,249 -187,965 | -55% | -$5.19M |
|
|
IMAB
15
I-MAB
IMAB
$340M
| $2.26M | 0.6% | 199,876 -849,815 | -81% | -$9.6M |
|
16
Immunovant
IMVT
$2.56B
| $2.26M | 0.6% | 579,061 -895,939 | -61% | -$3.49M |
|
|
RXDX
17
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $2.26M | 0.6% | 80,000 | – | – |
|
18
Century Therapeutics
IPSC
$42.5M
| $2.18M | 0.58% | 260,000 -398,266 | -61% | -$3.35M |
|
|
MREO
19
Mereo BioPharma
MREO
$272M
| $1.12M | 0.3% | +1,000,000 | New | +$1.12M |
|
|
AMAM
20
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $325K | 0.09% | 122,800 -26,600 | -18% | -$70.4K |
|
|
CNTB
21
Connect Biopharma
CNTB
$115M
| – | – | -279,921 | Closed | -$845K |
|
22
Dyne Therapeutics
DYN
$1.92B
| – | – | -525,284 | Closed | -$5.06M |
|
|
23
iTeos Therapeutics
ITOS
| – | – | -450,776 | Closed | -$14.5M |
|
|
OMGA
24
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| – | – | -176,470 | Closed | -$1.1M |
|
|
SURF
25
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| – | – | -2,300,000 | Closed | -$6.76M |
|